Prevalence of APC and PTEN Alterations in Urachal Cancer.


Journal

Pathology oncology research : POR
ISSN: 1532-2807
Titre abrégé: Pathol Oncol Res
Pays: Switzerland
ID NLM: 9706087

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 02 03 2020
accepted: 07 07 2020
pubmed: 6 8 2020
medline: 13 7 2021
entrez: 6 8 2020
Statut: ppublish

Résumé

Urachal carcinoma (UrC) is a rare tumor with remarkable histological and molecular similarities to colorectal cancer (CRC). Adenomatous polyposis coli (APC) is the most frequently affected gene in CRC, but the prevalence and significance of its alterations in UrC is poorly understood. In addition, loss of phosphatase and tensin homologue (PTEN) was shown to be associated with therapy resistance in CRC. Our primary aim was to assess specific genetic alterations including APC and PTEN in a large series of UrC samples in order to identify clinically significant genomic alterations. We analyzed a total of 40 UrC cases. Targeted 5-gene (APC, PTEN, DICER1, PRKAR1A, TSHR, WRN) panel sequencing was performed on the Illumina MiSeq platform (n = 34). In addition, ß-catenin (n = 38) and PTEN (n = 30) expressions were assessed by immunohistochemistry. APC and PTEN genes were affected in 15% (5/34) and 6% (2/34) of cases. Two of five APC alterations (p.Y1075*, p.K1199*) were truncating pathogenic mutations. One of the two PTEN variants was a pathogenic frameshift insertion (p.C211fs). In 29% (11/38) of samples, at least some weak nuclear ß-catenin immunostaining was detected and PTEN loss was observed in 20% (6/30) of samples. The low prevalence of APC mutations in UrC represents a characteristic difference to CRC. Based on APC and ß-catenin results, the Wnt pathway seems to be rarely affected in UrC. Considering the formerly described involvement of PTEN protein loss in anti-EGFR therapy-resistance its immunohistochemical testing may have therapeutic relevance.

Identifiants

pubmed: 32754865
doi: 10.1007/s12253-020-00872-6
pii: 10.1007/s12253-020-00872-6
pmc: PMC7471184
doi:

Substances chimiques

APC protein, human 0
Adenomatous Polyposis Coli Protein 0
Biomarkers, Tumor 0
beta Catenin 0
PTEN Phosphohydrolase EC 3.1.3.67
PTEN protein, human EC 3.1.3.67

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2773-2781

Subventions

Organisme : Nemzeti Kutatási, Fejlesztési és Innovaciós Alap (HU)
ID : NKFIH / PD 115616
Organisme : Nemzeti Versenyképességi és Kiválósági Program
ID : 16-1-2016-004

Références

Diagn Pathol. 2012 Nov 02;7:151
pubmed: 23121893
J Biomed Sci. 2016 Jan 19;23:9
pubmed: 26787105
Clin Genitourin Cancer. 2016 Aug;14(4):e449-52
pubmed: 27102403
Eur Urol. 2016 Nov;70(5):771-775
pubmed: 27178450
Virchows Arch. 2019 Jan;474(1):13-20
pubmed: 30302546
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Int J Cancer. 2018 Oct 1;143(7):1764-1773
pubmed: 29672836
Urol Oncol. 2016 Sep;34(9):388-98
pubmed: 27267737
Pol J Pathol. 2016 Jun;67(2):156-62
pubmed: 27543871
Hum Pathol. 2014 Feb;45(2):327-30
pubmed: 24355196
Clin Cancer Res. 2004 Feb 15;10(4):1401-8
pubmed: 14977843
J Med Genet. 2017 Aug;54(8):572-578
pubmed: 28348108
J Cancer Res Ther. 2014 Jul-Sep;10(3):571-4
pubmed: 25313741
Pathology. 2017 Apr;49(3):316-317
pubmed: 28285720
Am J Surg Pathol. 2014 Aug;38(8):1033-45
pubmed: 25025366
Oncotarget. 2016 May 17;7(20):29211-5
pubmed: 27078850
J Urol. 1982 Jan;127(1):40-2
pubmed: 7057501
BMC Cancer. 2016 Feb 29;16:170
pubmed: 26925973
Oncotarget. 2016 Jun 28;7(26):39293-39301
pubmed: 27283768
J Urol. 1984 Jan;131(1):1-8
pubmed: 6361280
Ann Oncol. 2009 Jan;20(1):84-90
pubmed: 18669866
Dis Markers. 2018 Mar 12;2018:7308168
pubmed: 29721106
Br J Cancer. 2007 Oct 22;97(8):1139-45
pubmed: 17940504
J Cell Sci. 2007 Oct 1;120(Pt 19):3327-35
pubmed: 17881494

Auteurs

Nikolett Nagy (N)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

Henning Reis (H)

Institute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.

Boris Hadaschik (B)

Department of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.

Christian Niedworok (C)

Department of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.

Orsolya Módos (O)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

Attila Szendrői (A)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

Krisztina Bíró (K)

National Institute of Oncology, Budapest, 1122, Hungary.

Thomas Hager (T)

Institute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.

Thomas Herold (T)

Institute of Pathology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany.

Jason Ablat (J)

Vancouver Prostate Centre, University of British Columbia, Vancouver, V6H 3Z6, Canada.

Peter C Black (PC)

Vancouver Prostate Centre, University of British Columbia, Vancouver, V6H 3Z6, Canada.

Krzysztof Okon (K)

Department of Pathomorphology, Jagiellonian University, 30252, Cracow, Poland.

Yuri Tolkach (Y)

Institute of Pathology, University of Bonn, 53113, Bonn, Germany.

Anita Csizmarik (A)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

Csilla Oláh (C)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

David Keresztes (D)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

Felix Bremmer (F)

Institute of Pathology, University of Göttingen, 37073, Göttingen, Germany.

Nadine T Gaisa (NT)

Institute of Pathology, RWTH Aachen University, 52074, Aachen, Germany.

Joerg Kriegsmann (J)

Cytology and Molecular Diagnostics Trier, Center for Histology, 54296, Trier, Germany.

Ilona Kovalszky (I)

1st Institute of Pathology and Expreimental Cancer Research, Semmelweis University, Budapest, 1085, Hungary.

András Kiss (A)

2nd Department of Pathology, Semmelweis University, Budapest, 1091, Hungary.

József Tímár (J)

2nd Department of Pathology, Semmelweis University, Budapest, 1091, Hungary.

Marcell A Szász (MA)

Cancer Center, Semmelweis University, Budapest, 1083, Hungary.

Michael Rink (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.

Margit Fisch (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, 20246, Hamburg, Germany.

Péter Nyirády (P)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary.

Tibor Szarvas (T)

Department of Urology, Semmelweis University, Budapest, 1082, Hungary. sztibusz@gmail.com.
Department of Urology, West German Cancer Center, University of Duisburg-Essen, University Hospital Essen, 45147, Essen, Germany. sztibusz@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH